



We appreciate your continued partnership and responsiveness in providing COVID-19 medical countermeasures to the American people. We are grateful for all you have done and all you continue to do to protect Americans in the fight against COVID-19.

We would like to share with you some important updates regarding one of our COVID-19 vaccines. Moderna-10 and Moderna-5 monovalent products for individuals aged 6 and older are set to expire in early April. There will not be any additional shelf-life extensions for these products.

The Moderna 6-11 and 12+ monovalent products ordered in the next few weeks will be short-dated, with expirations in early April. The U.S. government will accept orders for Moderna monovalent vaccines through March 13 to support primary series vaccinations. After March 13, providers will need to order alternative vaccines from Pfizer (ages 6 and older) and Novavax (aged 12 and older) for individuals seeking monovalent, primary series vaccines.

In anticipation of the upcoming expiration of Moderna's monovalent vaccines for people ages 6 and older, providers should be aware that depending on the date of the first Moderna dose, the same product may not be available to complete the primary series. In this case, a different COVID-19 vaccine may be administered to complete the primary series at a minimum interval of 28 days from the last COVID-19 vaccine dose. Please read CDC guidance on interchanging COVID-19 vaccines [here](#).

The U.S. government has an ample supply of monovalent vaccines produced by Pfizer (ages 6 and older) and Novavax (ages 12 and older) to begin and complete their primary series.

In summary:

- All Moderna adult (12+) and pediatric (6-11) monovalent COVID-19 vaccines will reach their expiry in early April.
- Moderna is not seeking a shelf-life extension for these vaccines.
- Ordering for Moderna adult (12+) and pediatric (6-11) monovalent COVID-19 vaccines will end on March 13. Ordering for Moderna bivalent vaccines for all age groups will remain available.
- Administration sites should be mindful of patients starting their primary series with Moderna adult (12+) or pediatric (6-11) monovalent vaccines. Depending on the date, they may not be able to complete their primary series with this product. In this case, a different COVID-19 vaccine may be administered to complete the primary series at a minimum interval of 28 days from the last COVID-19 vaccine dose.

· Pfizer (12+ and 5-11) and Novavax (12+) monovalent vaccines remain available for ordering for primary series vaccination. There is ample supply of both products, and providers can order additional supply.

Please send questions to COVIDVaccines@dhec.sc.gov.

03/06/2023